Dr. Ollerenshaw is Co-Founder and Chief Executive Officer at BetaBlue, Inc. He has a PhD from the University of Leicester in the UK and has worked in various R&D leadership capacities in the pharmaceutical and medical device industries for over 23 years. He has played an integral part in drug and medical device regulatory filings internationally and has published more than 60 scientific research articles as book chapters and in medical and scientific journals.
In 2011 Dr. Ollerenshaw Founded the Neurobiology Foundation, a 501(c)3 organization, that assists in the development of promising therapeutics to treat psychotic illness and he has a strong foundational knowlege of therapies for severe mental illness.
Dr. Ford is Co-founder and Chief Innovation Officer at BetaBlue, Inc. He has worked with the mentally ill since his teens and has completed a range of research projects in neuroscience. Most recently, Dr. Ford was a founder of NeuroNostix, a startup company seeking to commercialize dopamine receptor ligands from the National Institute of Neurological Disorders and Stroke (NINDS). He has provided consulting and business development services for various biomedical companies and has worked as a resident physician in both inpatient and outpatient settings, treating people with mental health problems.
Dr. Ford obtained his MS in Neuroscience from Tulane University, an MD from the UNC School of Medicine, and graduated Beta Gamma Sigma from the Kenan-Flagler Business School.
Dr. Montgomery is Co-Founder and Chief Development Officer at BetaBlue, Inc. He has a Ph.D. from Georgetown University Medical Center and has over 30 years of senior management experience in nonclinical drug and biological product development. He has worked in both industry and government (FDA). He has been involved in program design, conduct, evaluation, and successful regulatory IND/NDA submissions of drug candidates including neurological therapeutics.
Dr. Montgomery has served as a private consultant on nonclinical drug development for new ventures and established pharmaceutical entities.